乳腺癌新辅助化疗后残余腋窝淋巴结转移的预测:基于胸部计算机断层扫描的影像组学分析
本回顾性研究纳入226例临床淋巴结阳性乳腺癌患者,基于新辅助化疗前后胸部CT构建定性CT特征模型、影像组学模型及融合模型,预测残余腋窝淋巴结转移。新辅助化疗后CT的联合感兴趣区影像组学模型AUC为0.832,临床-影像组学模型AUC为0.866,定量影像组学分析可能优于定性CT特征模型。
要点
- 新辅助化疗后CT的临床-影像组学模型预测残余腋窝淋巴结转移AUC达0.866。
- 新辅助化疗后CT联合感兴趣区影像组学模型AUC为0.832,优于定性CT特征模型AUC 0.642。
- 临床N分期、生物学亚型及影像所示原发肿瘤反应与残余淋巴结转移相关。
核心结论
- 基于CT的预测模型对预测新辅助化疗后残余淋巴结转移显示出良好的诊断性能,定量影像组学分析可能提供比定性CT特征模型更高的性能。
研究设计与样本
- 回顾性研究,纳入226例临床淋巴结阳性乳腺癌女性(平均年龄51.4岁),于2015年1月至2021年7月接受新辅助化疗后手术,按4:1随机分为训练集和测试集。
关键影像表现/征象
- 基于三位放射科医师视觉判读汇总数据的腋窝淋巴结定性CT特征,采用逻辑回归构建定性CT特征模型。
- 分别在新辅助化疗前CT和新辅助化疗后CT上勾画结内、结周及联合三种不同感兴趣区,采用梯度提升分类器构建三个影像组学模型。
- 融合模型将临床病理因素分别与定性CT特征模型(临床-定性CT特征模型)或联合感兴趣区影像组学模型(临床-影像组学模型)整合。
诊断标准与关键数值
- 新辅助化疗后CT定性CT特征模型AUC为0.642。
- 新辅助化疗后CT结内、结周及联合感兴趣区影像组学模型AUC分别为0.812、0.762和0.832。
- 新辅助化疗后CT临床-定性CT特征模型AUC为0.740,临床-影像组学模型AUC为0.866。
- 多因素分析显示临床N分期、生物学亚型及影像所示原发肿瘤反应与残余淋巴结转移相关(均P < 0.05)。
临床应用与阅片要点
- 作者认为定量影像组学分析可能提供比定性CT特征模型更高的预测性能。
- 作者建议应开展更大规模的多中心研究以确认其性能。
局限性
- 原文建议应开展更大规模的多中心研究以确认模型性能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the diagnostic performance of chest computed tomography (CT)-based qualitative and radiomics models for predicting residual axillary nodal metastasis after neoadjuvant chemotherapy (NAC) for patients with clinically node-positive breast cancer.
MATERIALS AND METHODS: This retrospective study included 226 women (mean age, 51.4 years) with clinically node-positive breast cancer treated with NAC followed by surgery between January 2015 and July 2021. Patients were randomly divided into the training and test sets (4:1 ratio). The following predictive models were built: a qualitative CT feature model using logistic regression based on qualitative imaging features of axillary nodes from the pooled data obtained using the visual interpretations of three radiologists; three radiomics models using radiomics features from three (intranodal, perinodal, and combined) different regions of interest (ROIs) delineated on pre-NAC CT and post-NAC CT using a gradient-boosting classifier; and fusion models integrating clinicopathologic factors with the qualitative CT feature model (referred to as clinical-qualitative CT feature models) or with the combined ROI radiomics model (referred to as clinical-radiomics models). The area under the curve (AUC) was used to assess and compare the model performance.
RESULTS: Clinical N stage, biological subtype, and primary tumor response indicated by imaging were associated with residual nodal metastasis during the multivariable analysis (all P < 0.05). The AUCs of the qualitative CT feature model and radiomics models (intranodal, perinodal, and combined ROI models) according to post-NAC CT were 0.642, 0.812, 0.762, and 0.832, respectively. The AUCs of the clinical-qualitative CT feature model and clinical-radiomics model according to post-NAC CT were 0.740 and 0.866, respectively.
CONCLUSION: CT-based predictive models showed good diagnostic performance for predicting residual nodal metastasis after NAC. Quantitative radiomics analysis may provide a higher level of performance than qualitative CT features models. Larger multicenter studies should be conducted to confirm their performance.
引用
- Lee HJ, Nguyen AT, Song MW, et al. Prediction of Residual Axillary Nodal Metastasis Following Neoadjuvant Chemotherapy for Breast Cancer: Radiomics Analysis Based on Chest Computed Tomography. Korean J Radiol. 2023. PMID: 37271204. doi:10.3348/kjr.2022.0731
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。